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Plasma Cell Disorders
Introduction
Multiple myeloma (MM) is an incurable hematologic
malignancy that mainly affects elderly individuals, and is
characterized by the proliferation of plasma cells.1 Five-year
relative survival rates have been shown to diminish with
increasing patient age; however, improved survival rates have
been reported in newly diagnosed MM (NDMM) patients in
recent years since the introduction of novel agents such as
thalidomide, lenalidomide, and bortezomib.2-4 
Melphalan and prednisone (MP) combined with thalido-
mide (MPT) or bortezomib (MPV) are considered standard
first-line treatment options in elderly NDMM patients who
are ineligible for autologous stem cell transplantation.5-13
Although lenalidomide in combination with low-dose dex-
amethasone (Rd) is an established standard treatment option
in patients with relapsed/refractory MM, recent data have
emerged on the efficacy of this combination in patients with
NDMM.1,5,10,11,14-18
The randomized pivotal phase III FIRST trial (Frontline
Investigation of lenalidomide/dexamethasone [Rev/Dex] ver-
sus Standard Thalidomide; IFM 2007-01/MM-020; clinicaltri-
als.gov identifier: 00689936; EudraCT No. 2007-004823-39)
compared the efficacy and safety of Rd, administered contin-
uously until progressive disease (PD) or for a fixed 18-month
duration (Rd18), with MPT given for 18 months in NDMM
patients who were aged 65 years or over, or who were aged
under 65 years and ineligible for stem cell transplantation.
Continuous Rd showed improved progression-free survival
(PFS) and overall survival (OS) benefit at interim analysis
compared with MPT.19
Although extending survival is clearly the ultimate treatment
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We compared the health-related quality-of-life of patients with newly diagnosed multiple myeloma aged over 65
years or transplant-ineligible in the pivotal, phase III FIRST trial. Patients received: i)  continuous lenalidomide and
low-dose dexamethasone until disease progression; ii) fixed cycles of lenalidomide and low-dose dexamethasone
for 18 months; or iii) fixed cycles of melphalan, prednisone, thalidomide for 18 months. Data were collected using
the validated questionnaires (QLQ-MY20, QLQ-C30, and EQ-5D). The analysis focused on the EQ-5D utility
value and six domains pre-selected for their perceived clinical relevance. Lenalidomide and low-dose dexametha-
sone, and melphalan, prednisone, thalidomide improved patients’ health-related quality-of-life from baseline over
the duration of the study across all pre-selected domains of the QLQ-C30 and EQ-5D. In the QLQ-MY20, lenalido-
mide and low-dose dexamethasone demonstrated a significantly greater reduction in the Disease Symptoms
domain compared with melphalan, prednisone, thalidomide at Month 3, and significantly lower scores for QLQ-
MY20 Side Effects of Treatment at all post-baseline assessments except Month 18. Linear mixed-model repeated-
measures analyses confirmed the results observed in the cross-sectional analysis. Continuous lenalidomide and
low-dose dexamethasone delays disease progression versusmelphalan, prednisone, thalidomide and has been asso-
ciated with a clinically meaningful improvement in health-related quality-of-life. These results further establish
continuous lenalidomide and low-dose dexamethasone as a new standard of care for initial therapy of myeloma
by demonstrating superior health-related quality-of-life during treatment, compared with melphalan, prednisone,
thalidomide.
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ABSTRACT
goal of myeloma therapy, reducing disease-related symp-
toms and improving quality-of-life (QoL) are equally impor-
tant. MM patients have a high symptom burden, including
pain and fatigue, which are associated with reduced overall
health-related QoL (HRQoL), particularly in relation to
physical functioning.20-23 In this population, treatment objec-
tives should be to improve disease management by delay-
ing disease progression, optimizing response, and prolong-
ing survival. In addition, it is particularly important in elder-
ly patients to maintain QoL and minimize treatment-relat-
ed toxicity and discomfort.24,25 Therefore, we incorporated
patient-reported measures in the FIRST trial to determine if
the choice of initial therapy regimen resulted in differences
in symptom burden and HRQoL over time. 
Methods
Trial design
The FIRST trial was a pivotal phase III, randomized, open-label,
3-arm, international study. Study details have been published pre-
viously.18 Briefly, transplant-ineligible NDMM patients were ran-
domized to continuous Rd in 28-day cycles until PD (n=535), to
Rd18 (Rd in 28-day cycles for 18 cycles; 72 weeks) (n=541), or to
MPT in 42-day cycles for 12 cycles (72 weeks) (n=547). HRQoL
was a secondary end point, and data were collected for a maxi-
mum of 18 months or until PD using three validated question-
naires. For the purpose of this HRQoL analysis, and because the
continuous Rd and Rd18 regimens were identical over the 18
months, the two lenalidomide arms were collated into one “Rd”
arm in a post hoc fashion. The trial protocol was approved by each
study site’s Independent Ethics Committee or Institutional Review
Board, and the study was conducted in accordance with the
Declaration of Helsinki.
HRQoL assessments
HRQoL was evaluated with the myeloma-specific QLQ-MY20
questionnaire as well as with the general oncology-related QLQ-
C30 and the generic EuroQoL EQ-5D surveys.26-35 These question-
naires were administered in paper format at the hospital. Patients
completed the questionnaires at several time points: baseline; at
the end of Cycle 1 (after 4 weeks of treatment with Rd and after 6
weeks of treatment with MPT); after 3, 6, 12, and 18 months of
treatment; and at study discontinuation. These questionnaires are
among the most extensively validated in MM36 and can be easily
completed with minimal patient burden.37,38 The analysis focused
on the EQ-5D utility value and six pre-selected and clinically rele-
vant HRQoL domains: two from the QLQ-MY20 (Disease
Symptoms and Side Effects of Treatment); and four from the
QLQ-C30 (Global Health Status, Physical Functioning, Fatigue,
and Pain). These domains were chosen before data analysis fol-
lowing a workshop discussion with hematologists, and were
based on perceived clinical relevance. Full results from all domains
are presented in the Online Supplementary Appendix and are gener-
ally in line with the results presented. 
EQ-5D, QLQ-MY20, and QLQ-C30 domains were scored in
accordance with their published guidelines.27,28,32,37,38 Results were
transformed into scales ranging from 0 to 100 for QLQ-MY20 and
QLQ-C30. For the functional scales (Global Health Status and
Physical Functioning), higher scores indicate better HRQoL,
whereas for the symptom scales (Fatigue, Pain, Disease
Symptoms, and Side Effects of Treatment), lower scores indicate a
better health state. Health utility values were derived from the
EQ-5D using the UK general population weights algorithm,28
which provides a range of scores from worst imaginable health
state (−0.594) to best imaginable health state (1.000).
Statistical analyses
Compliance rates at each scheduled assessment were calculated
as the number of compliant patients divided by the number of
patients with clinical data at that assessment. Analyses were per-
formed on intention-to-treat patients; data cut off was May 24,
2013, corresponding to a median follow up of 37 months. In accor-
dance with scoring requirements, patients were considered com-
pliant if half of the questions from the QLQ-MY20 and QLQ-C30
were completed, and if all the questions from the EQ-5D were
answered. Cross-sectional and longitudinal HRQoL analyses and
estimation of overall treatment effects were performed and are
described in detail in the Online Supplementary Appendix.
In order to assess if statistical differences translated into clinical-
ly meaningful differences/improvements, the minimal important
difference (MID) associated with each domain was considered.
MM-specific MIDs were applied to the QLQ-C30 and QLQ-
MY20 domains: Global Health Status (MID=7); Physical
Functioning (MID=9); Pain (MID=12); Fatigue (MID=10); Disease
Symptoms (MID=10); and Side Effects of Treatment
(MID=6).30,39,40 The Walters and Brazier41 MID of 0.07 was applied
to the EQ-5D utility. Rigorous MID methods, in which the mean
and 95% confidence intervals (CI) of change must meet the MID,
were applied and are reported where relevant. 
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Table 1. Base-line characteristics of patients included in the health-
related quality-of-life analysis.
Characteristic Rd MPT
(n=1076) (n=547)
Age, years Median (range) 73.0 (40.0-91.0) 73.0 (51.0-92.0)
Age group <65 years 65 (6.0) 27 (4.9)
65-75 years 632 (58.7) 332 (60.7)
>75 years 379 (35.2) 188 (34.4)
Sex Male 567 (52.7) 287 (52.5)
Race White 954 (88.7) 491 (89.8)
Asian 83 (7.7) 44 (8.0)
Other 39 (3.6) 12 (2.2)
Region Europe 739 (68.7) 374 (68.4)
North America 263 (24.4) 133 (24.3)
Other 74 (6.9) 40 (7.3)
ECOG PS 0 318 (29.6) 156 (28.5)
1 520 (48.3) 275 (50.3)
2 232 (21.6) 111 (20.3)
≥3 4 (0.4) 2 (0.4)
Missing 2 (0.2) 3 (0.5)
ISS stage 1-2 641 (59.6) 323 (59.0)
3 435 (40.4) 224 (41.0)
Myeloma type IgG 665 (61.8) 350 (64.0)
IgA 280 (26.0) 123 (22.5)
Other 131 (12.2) 74 (13.5)
β2 microglobulin, ≤5.5 625 (58.1) 312 (57.0)
mg/L >5.5 448 (41.6) 234 (42.8)
Missing 3 (0.3) 1 (0.2)
Albumin level, g/L ≤3.5 401 (37.3) 223 (40.8)
>3.5 674 (62.6) 324 (59.2)
Missing 1 (0.1) 0
CrCl, mL/min <30 92 (8.6) 55 (10.1)
≥30 to <50 246 (22.9) 126 (23.0)
≥50 738 (68.6) 366 (66.9)
All values n (%) unless stated otherwise. CrCl: creatinine clearance; ECOG PS: Eastern
Cooperative Oncology Group performance status; Ig: immunoglobulin; ISS:
International Staging System; MPT: melphalan, prednisone, thalidomide; Rd: lenalido-
mide and low-dose dexamethasone.
To complement the patient-reported Side Effects of Treatment
data (QLQ-MY20 domain), a selection of the most predominant
and clinically meaningful hematologic and non-hematologic grade
3-4 adverse events (AEs) is presented up to 24 months for patients
receiving continuous Rd. The selected AEs presented here reflect
closely those in previous reports of the FIRST study.18,19 
Results
Base-line characteristics 
The FIRST study randomized a total of 1623 patients to
Rd (n=1,076) versusMPT (n=547). Base-line patients’ charac-
teristics were well balanced between treatment arms (Table
1), and no statistically significant differences in HRQoL
scores between groups were observed at baseline (Table 2). 
Compliance 
Rates with each of the questionnaires were high, partic-
ularly at the end of Cycle 1, and after 3 and 6 months
(≥84%), and were similar between treatment arms.
However, at Month 12 and Month 18, compliance rates
were significantly lower in the MPT arm versus the Rd arm
for all questionnaires (Table 3). Compliance at the study
discontinuation visit was the lowest (approx. 53%-59%)
of all the assessment visits in both treatment arms, but
was not statistically significantly different between groups
(Table 3).
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Figure 1. Cross-sectional analysis of mean HRQoL score changes
from baseline per assessment visit and at study discontinuation in
the Rd and MPT arms (EORTC QLQ-C30 and QLQ-MY20 total score
range 1 to 100; EQ-5D total score range -0.594 to 1.000). (A) EORTC
QLQ-C30. (B) EORTC QLQ-MY20. (C) EQ-5D.  +Significant within-group
change from baseline (P<0.05, 1-sample t-test). *Significant
between-group difference in change from baseline (P<0.05, 2-sam-
ple t-test). aSD can occur at any time point. EORTC: European
Organisation for Research and Treatment of Cancer; HRQoL: health-
related quality-of-life; MPT: melphalan, prednisone, thalidomide; Rd:
lenalidomide and low-dose dexamethasone; SD: study discontinua-
tion.
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HRQoL results 
Statistically significant symptom relief, as measured by
the QLQ-C30 Pain and Fatigue domains and QLQ-MY20
Disease Symptoms domain, was achieved in both arms.
Both treatment arms showed statistically significant
(P<0.05) reductions in pain (QLQ-C30 Pain and QLQ-
MY20 Disease Symptoms domains) at all post-baseline
assessments (Figure 1A and B). When an MID score of 12
for Pain (including the lower bound 95% CI) was applied,
Rd demonstrated clinically meaningful improvement at
Months 6 and 12, whereas MPT showed no clinically
meaningful improvement. Rd demonstrated a significantly
greater reduction in QLQ-MY20 Disease Symptoms com-
pared with MPT at Month 3 (P=0.04), and an overall lower
symptom score across all assessments (Figure 1B). The Rd
arm also showed significant improvement in Fatigue from
baseline at Month 3, Month 6, and Month 12 (Figure 1A).
Although both arms showed worsening in the Side Effects
of Treatment domain, as measured by the QLQ-MY20,
the Rd arm showed consistently lower scores (fewer/less
severe side-effects) across all post-baseline assessments,
with all but Month 18 being statistically significantly
(P<0.05) lower than the MPT arm (Figure 1B). The Side
Effects of Treatment MID of 6 was not reached by any
regimen; for Rd, the maximum score was 3.3 and for MPT
it was 5.6.
To assess the tolerability of prolonged administration of
lenalidomide and low-dose dexamethasone (continuous
Rd arm), we analyzed selected grade 3-4 AEs by time of
onset in the continuous Rd arm for patients who received
lenalidomide for more than 24 months; the selected events
occurred in 201 of 532 patients (Table 4). During the over-
all study period, neutropenia was the only grade 3-4 AE
Health-related quality-of-life in multiple myeloma
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Table 2. Mean scores of the selected HRQoL domains at baseline.
HRQoL domains.
HRQoL domains                           Rd                                   MPT
                                              (n=1076)                          (n=547)
QLQ-C30                                                                                                  
Global Health Status                  51.7 (24.4)                             50.8 (24.2)
Physical Functioning                  61.5 (27.0)                             59.9 (28.8)
Fatigue                                          44.8 (27.8)                             46.0 (28.4)
Pain                                                44.7 (33.6)                             45.3 (35.4)
QLQ-MY20                                                                                               
Disease symptoms                     30.1 (22.3)                             30.3 (22.7)
Side effects of treatment         19.8 (15.6)                             20.1 (15.9)
EQ-5D                                                                                                      
Health utility                                  0.5 (0.4)                                 0.5 (0.4)
All values mean (standard deviation). HRQoL: health-related-quality-of life; MPT: mel-
phalan, prednisone, thalidomide; Rd: lenalidomide and low-dose dexamethasone.
Table 3. Health-related quality-of-life reporting compliance.
                                                         Rd                                 MPT
                                                   (n=1076)                         (n=547)
EORTC Compliance Quotient QLQ-C30
Cycle 1a                                             918/997 (92.1)                      438/482 (90.9)
Month 3                                            876/927 (94.5)                      412/439 (93.8)
Month 6                                            784/871 (90.0)                      368/417 (88.2)
Month 12                                         634/702 (90.3)*                    263/325 (80.9)
Month 18                                         506/593 (85.3)*                    189/282 (67.0)
Study discontinuation                   492/843 (58.4)                      267/461 (57.9)
EORTC Compliance Quotient QLQ-MY20
Cycle 1a                                             916/997 (91.9)                      433/482 (89.8)
Month 3                                            869/927 (93.7)                      410/439 (93.4)
Month 6                                            780/871 (89.6)                      366/417 (87.8)
Month 12                                         632/702 (90.0)*                    262/325 (80.6)
Month 18                                         507/593 (85.5)*                    188/282 (66.7)
Study discontinuation                   490/843 (58.1)                      267/461 (57.9)
Compliance Quotient EQ-5D                                                                  
Cycle 1a                                             868/997 (87.1)                      414/482 (85.9)
Month 3                                            829/927 (89.4)                      392/439 (89.3)
Month 6                                            739/871 (84.8)                      350/417 (83.9)
Month 12                                         600/702 (85.5)*                    245/325 (75.4)
Month 18                                         473/593 (79.8)*                    182/282 (64.5)
Study discontinuation                   450/843 (53.4)                      252/461 (54.7)
All data n/N (%).  aWeek 4 assessment for Rd arm and week 6 assessment for MPT
arm. *P<0.05. EORTC: European Organisation for Research and Treatment of Cancer;
MPT: melphalan, prednisone, thalidomide; Rd: lenalidomide and low-dose dexametha-
sone.
Table 4. Selected grade 3-4 adverse events reported in more than 2% of patients by onset period for patients in the lenalidomide and low-dose
dexamethasone arm.
System Organ Class preferred terma Incidence (%)
Month Month Month Month
0-6 6-12 12-18 18-24
Hematologic
Anemia 6.0 2.0 2.5 2.0
Neutropenia 14.9 10.9 10.0 6.5
Leukopenia 3.0 1.0 2.0 1.0
Thrombocytopenia 2.0 3.0 2.5 0.5
Non-hematologic
Infection 7.5 8.5 3.5 9.0
Pneumonia 1.5 2.5 1.0 1.5
Diarrhea 1.0 1.5 2.0 2.0
Constipation 1.5 0.5 0.0 0.5
Peripheral sensory neuropathy 0.0 0.5 2.0 2.0
Deep-vein thrombosis 5.5 1.0 1.0 1.0
Pulmonary embolism 1.5 0.5 0.5 1.5
Cataract 0.5 1.5 2.0 3.5
aCoded using the  Medical Dictionary for Regulatory Activities (MedDRA) version 15.1. If the same adverse event was reported multiple times within a given preferred term, only
one event with the worst severity was counted per patient.
reported in 10% or over of patients receiving prolonged
treatment, and was reported most frequently during the
first six months. The incidence of anemia was highest dur-
ing the first six months and decreased over time.
Both Rd regimens and MPT improved patients’ HRQoL
from baseline over the duration of the study across all pre-
selected domains of the QLQ-C30 and EQ-5D question-
naires, but HRQoL dropped at progression. Statistically
significant improvement (P<0.05) from baseline was
observed in both treatment arms for functional scales
Global Health Status, Physical Functioning, and EQ-5D
Health Utility (Figure 1A and C) at all time points after
Cycle 1. No statistically significant differences between
treatment arms were reported for Global Health Status,
Physical Functioning, and EQ-5D Health Utility. However,
the Rd treatment arm demonstrated consistent clinically
meaningful improvement in HRQoL as measured by 
EQ-5D at all post-baseline assessments except at Month 1.
The MPT treatment arm demonstrated clinically meaning-
ful improvement only at Month 3.
Mixed-model analysis 
Results of the linear mixed-model repeated-measures
analyses confirmed those observed in the cross-sectional
analysis. Significant within-treatment improvements over
time were observed in both treatment arms in all domains
except Fatigue and Side Effects of Treatment (Figure 2A).
A significant (P<0.0001) between-group difference in
mean change from baseline was observed for the Side
Effects of Treatment domain in favor of the Rd arm, indi-
cating fewer severe side effects than the MPT arm (Figure
2B).
Effect of age on HRQoL outcomes 
We compared the difference in mean change from base-
line between the Rd and MPT arms for patients aged 75
years or under (Rd, n=697; MPT, n=359) and over 75 years
(Rd, n=379; MPT, n=188) in a post hoc analysis (Figure 3).
Overall, within- and between-treatment HRQoL out-
comes in patients aged 75 years or under were consistent
with those observed for the overall study population,
except Fatigue, which significantly improved from base-
line in the Rd arm (P=0.0002), but not in the MPT arm.
Changes in Side Effects of Treatment on the MM-specific
QLQ-MY20 questionnaire showed a statistically signifi-
cant benefit (fewer/less severe side effects) for Rd over the
MPT arm in both age groups (P<0.05) (Figure 3A). In
patients aged over 75 years, Pain and Disease Symptoms
both showed significant improvement across treatment
arms. Rd demonstrated statistically significant improve-
ment for Health Utility. Fatigue significantly declined in
both treatment arms. Physical Functioning scores declined
significantly in the MPT arm, but not in the Rd arm, and
were significantly (P<0.05) better in the Rd arm versus the
MPT arm (Figure 3B). 
Discussion
We show that the improved PFS with Rd is accompa-
nied by an improvement in HRQoL, showing both statis-
tically significant and clinically meaningful changes from
baseline. Rd showed statistical superiority to MPT in Side
Effects of Treatment, and no evidence of inferiority to
MPT in any of the pre-selected HRQoL domains. This
finding is of importance because it demonstrates that the
improved PFS in this study does not come at a cost of
increased symptoms or decreased HRQoL.
The FIRST study is the largest phase III trial conducted
in transplant-ineligible elderly NDMM patients to date,
and the first to evaluate HRQoL in NDMM patients
receiving Rd. Primary efficacy results from this study indi-
cated that continuous Rd administration significantly
improved PFS and OS at the interim analysis compared
with the MPT regimen,19 highlighting a double paradigm
change in a setting in which alkylating agents and fixed-
M. Delforge et al.
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Figure 2. Linear mixed-model repeated-measures analysis of mean
change from baseline and mean difference in change from baseline
at 18 months in the Rd and MPT arms. (A) Mean change from base-
line at 18 months. (B) Least-squares mean difference in change from
baseline for Rd versus MPT at 18 months. Error bars represent 95%
confidence intervals.  *P<0.05. EORTC: European Organisation for
Research and Treatment of Cancer; HRQoL: health-related quality-of-
life; MPT: melphalan, prednisone, thalidomide; Rd: lenalidomide and
low-dose dexamethasone.
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duration chemotherapy have long been considered treat-
ment standards. Indeed, non-MP regimens are increasingly
challenging traditional melphalan-based approaches in
NDMM patients, as seen from randomized phase III trial
data, including E4A0314 and UPFRONT.42 The observed
differences in HRQoL between continuous Rd and MPT
likely reflect both the good tolerability of the Rd regimen
(leading to fewer side effects of treatment) and prolonged
time to progression with continuous Rd. Improvements in
HRQoL have previously been reported during treatment
with melphalan, prednisone, lenalidomide followed by
lenalidomide maintenance (MPR-R) in patients with
NDMM,39,43 and the addition of thalidomide to MP did not
negatively affect HRQoL.44 However, our results contrast
with the HRQoL trade-off reported with bortezomib in
the VISTA trial, which compared MPV versus MP in
NDMM patients and in which MPV had superior PFS and
OS efficacy, but where patients’ HRQoL was significantly
compromised, especially in the first four cycles of treat-
ment.45,46 
In the FIRST trial, although HRQoL was improved and
maintained during the progression-free state, it deteriorat-
ed when disease progression occurred, regardless of the
treatment received. This finding augments the clinical
importance/benefit of the prolonged PFS, and time to pro-
gression observed with Rd versusMPT,19 as a longer PFS in
this comparison is associated with better HRQoL. Rd
treatment demonstrated significant improvement in the
Disease Symptoms domain and significantly lower scores
for the MM-specific QLQ-MY20 Side Effects of Treatment
domain at specific time points versusMPT (although not to
the level of MID). Improvements corresponded with a
lower incidence of neurotoxicity and hematologic AEs
with Rd, a higher discontinuation rate with MPT, and
improved response rates with continuous Rd and Rd18
(75.1% and 73.4%, respectively, versus 62.3% with MPT),
as seen in the primary efficacy data.19 Treatment with
MPT was associated with greater HRQoL worsening in
the Side Effects of Treatment domain compared with Rd
treatment. Indeed, higher rates of grade 3-4 neutropenia,
leukopenia, constipation, and peripheral neuropathy were
observed in the MPT arm,19 which may explain the lower
rate of HRQoL compliance among patients randomized to
MPT. Indeed, previous studies have reported that the
addition of thalidomide to MP results in increased grade 3-
4 toxicity.6,47 In our study, the Rd doublet regimen was bet-
ter tolerated than MPT over time. Patients who received
MPT discontinued treatment sooner and experienced AEs
leading to study drug discontinuation prior to PD more
frequently than those randomized to Rd.19 We have now
shown that HRQoL improved after treatment initiation
and was generally maintained while patients were pro-
gression-free, but deteriorated with PD. The HRQoL
decrease upon PD captured quantitatively here is also con-
sistent with qualitative results on the burden of relapse on
MM patients’ emotional and physical well-being.48 This
adds additional support to the validity of the HRQoL
measures included in the FIRST trial; further evidence of
their reliability was also seen in the similarity in base-line
scores between the FIRST, VISTA,45 and HOVON 4949
studies. 
Analysis by age showed that, compared with MPT, Rd
treatment did not negatively affect general HRQoL in
patients aged over 75 years. Indeed, only Rd showed a sta-
tistically significant improvement in EQ-5D Health Utility
in this age group, and also showed significantly less wors-
ening of Physical Functioning scores compared with MPT.
Both treatment arms showed improvement in the pain
scales.
The sustained improvement in HRQoL reported in the
present study is indicative of good tolerability. One caveat,
however, is that we did not collect HRQoL data beyond
18 months of treatment; therefore, we are unable to draw
conclusions on the effects of long-term continuous Rd
Health-related quality-of-life in multiple myeloma
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Figure 3. Linear mixed-model repeated-measures analysis: change
from baseline at 18 months in patients aged ≤75 years in the Rd and
MPT arms. (A) Patients aged ≤75 years. (B) Patients aged >75 years.
*P<0.05 for between-group estimated difference in mean change
from baseline. EORTC: European Organisation for Research and
Treatment of Cancer; HRQoL: health-related quality-of-life; MPT: mel-
phalan, prednisone, thalidomide; Rd: lenalidomide and low-dose dex-
amethasone. 
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treatment on patients’ HRQoL. This is of particular signif-
icance as, in addition to the FIRST trial, several clinical
studies support the value of continuous versus fixed-dura-
tion treatment, making it important that the improved
clinical outcomes do not come at the cost of reduced
HRQoL. To try to answer this question, we carried out an
exploratory analysis to look for trends in AEs during up to
two years of treatment. The analysis did not show an
increase in incidence of AEs during Months 18-24, sug-
gesting that, from the perspective of side effects, HRQoL
does not deteriorate beyond 18 months of treatment.
Furthermore, during the MM-015 phase III trial, with a
median follow up of 30 months, more patients treated
with MPR-R achieved minimal important improvements
in HRQoL outcomes compared with those on MP, and
there were no significant differences in HRQoL outcomes
between patients on continuous treatment versus place-
bo.39,43 
Although not all the statistically significant changes
reached the MID threshold, Rd showed evidence of clini-
cally meaningful improvement in Pain and in HRQoL as
measured by EQ-5D, whereas MPT failed to demonstrate
a clinically meaningful improvement in any domain (with
the exception of 1 time point in EQ-5D). Neither treat-
ment showed a clinically significant worsening of HRQoL
in any domain. With regard to the Side Effects of
Treatment domain, MID analysis showed that patients in
the MPT arm approached the negative MID threshold of
6, whereas those in the Rd arm did not.
Future analyses should investigate MID at the individual
patient level to understand what proportion of patients
experienced a clinically meaningful improvement in each
treatment group and whether there is a difference
between groups. 
In summary, efforts to improve progression-free intervals
and survival are essential in the case of an incurable disease
such as MM. However, it is just as important to ensure that
a patient’s HRQoL is maintained and not compromised dur-
ing the extended survival period and that the side-effects of
treatment are not worse than the disease symptoms.
Continuous lenalidomide treatment has been shown to fur-
ther improve PFS and disease outcomes, and improved sur-
vival rates have been reported in NDMM patients in recent
years. The manageable and favorable toxicity and HRQoL
profiles of Rd versus MPT may facilitate patient adherence,
positioning the alkylator-free oral Rd regimen as a very effi-
cient and well-tolerated treatment in a first-line setting. Our
results further establish the combination of lenalidomide
and low-dose dexamethasone as a new standard of care for
initial therapy of myeloma by demonstrating superior QoL
during treatment compared with MPT, although longer-
term follow up data (>18 months) on cumulative toxicity
and HRQoL are needed.50
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